Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/Ivax Merger Gets FTC OK Pending Divestitures

This article was originally published in The Pink Sheet Daily

Executive Summary

Par and Barr will acquire 15 of the companies’ generic offerings.
Advertisement

Related Content

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
Teva Incoming CEO Yanai To Take The Helm In First Half 2007
Teva Incoming CEO Yanai To Take The Helm In First Half 2007
Merck’s Discounted Zocor Has Had “Negligible Impact,” Teva Says
Merck’s Discounted Zocor Has Had “Negligible Impact,” Teva Says
Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006
Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006
Teva Could Modify Its "Authorized" Generic Policy Following Ivax Acquisition
Teva Could Modify Its "Authorized" Generic Policy Following Ivax Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS063078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel